CDKN2A and neoplasm: A meta-analysis involving 3440 CRC patients encompassing stage I to stage IV tumours revealed that individuals with LVI or lymph node metastasis had a higher likelihood (1.68 times) of exhibiting CDKN2A hypermethylation than patients without LVI or lymph node metastasis (positive vs. negative: an odds rations of 1.68) [58].